2008
DOI: 10.1016/j.maturitas.2007.10.003
|View full text |Cite
|
Sign up to set email alerts
|

Circulating leptin and ghrelin are differentially influenced by estrogen/progestin therapy and raloxifene

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
21
1
3

Year Published

2010
2010
2016
2016

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 23 publications
(27 citation statements)
references
References 73 publications
2
21
1
3
Order By: Relevance
“…Thus, it is not surprising that leptin or Lepr signaling (the key negative regulatory hormone for body fat (42)) also plays a negative regulatory role in bone responsiveness to mechanical loading. More importantly, the findings that 1) the increase in obesity in postmenopausal women is associated with an increase in the circulating leptin level (43), 2) estrogen replacement in post- menopausal women decreases serum leptin levels (44), and 3) the PvuII and XbaI polymorphisms of ER␣ significantly influence the association between the Q223R polymorphism of human LEPR and peak bone mineral density (45) raise the interesting possibility that the suppressive action of leptin or Lepr signaling on bone mechanosensitivity might also have a role in the reduction in bone formation in postmenopausal osteoporotic patients. Our future studies will address these very interesting possibilities.…”
Section: Discussionmentioning
confidence: 99%
“…Thus, it is not surprising that leptin or Lepr signaling (the key negative regulatory hormone for body fat (42)) also plays a negative regulatory role in bone responsiveness to mechanical loading. More importantly, the findings that 1) the increase in obesity in postmenopausal women is associated with an increase in the circulating leptin level (43), 2) estrogen replacement in post- menopausal women decreases serum leptin levels (44), and 3) the PvuII and XbaI polymorphisms of ER␣ significantly influence the association between the Q223R polymorphism of human LEPR and peak bone mineral density (45) raise the interesting possibility that the suppressive action of leptin or Lepr signaling on bone mechanosensitivity might also have a role in the reduction in bone formation in postmenopausal osteoporotic patients. Our future studies will address these very interesting possibilities.…”
Section: Discussionmentioning
confidence: 99%
“…In ovariectomized rats, raloxifene treatment reversed estrogen deficiency-induced hyperleptinemia and reduced total fat mass [45]. In two clinical studies conducted in postmenopausal women, raloxifene treatment (lasting for 3 and 6 months, respectively) significantly increased serum leptin level compared to baseline [59,60]. In contrast, another study found that serum leptin levels remained unchanged compared to baseline in postmenopausal women receiving raloxifene treatment, although serum leptin levels were significantly lower in postmenopausal women receiving raloxifene compared to those receiving no treatment [61].…”
Section: The Effects Of Raloxifene On Metabolismmentioning
confidence: 97%
“…Precise mechanism for the discrepancy remains unknown, but may relate to the distinction of age (Matsubara et al, 2004), physiological status (Chu et al, 2006) and variation in methods used for estrogen application (Kellokoski et al, 2005;Chu et al, 2006). Estrogen replacement therapy in post-menopausal women has been reported to induce increase (Kellokoski et al, 2005;Lambrinoudaki et al, 2008), no significant change, or even decreases (Chu et al, 2006) in serum total and acyl ghrelin secretion. In female rats, ovariectomy induces a transient augment in plasma acyl ghrelin, ghrelin expressing cells and ghrelin mRNA in stomach (Matsubara et al, 2004).…”
Section: Ghrelin and Estrogenmentioning
confidence: 99%